AA
OMED

ALPS Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

ALPS Advisors’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-31,910
Closed -$294K – 803
2017
Q1 		$294K Sell
31,910
-3,735
-10% -$32.8K ﹤0.01% 695
2016
Q4 		$275K Sell
35,645
-10,102
-22% -$92.8K ﹤0.01% 677
2016
Q3 		$523K Buy
45,747
+3,185
+7% +$37.1K ﹤0.01% 263
2016
Q2 		$524K Buy
42,562
+8,701
+26% +$106K ﹤0.01% 248
2016
Q1 		$342K Sell
33,861
-5,802
-15% -$68.1K ﹤0.01% 576
2015
Q4 		$894K Sell
39,663
-7,323
-16% -$150K 0.01% 220
2015
Q3 		$7.79K Buy
46,986
+17,206
+58% +$345K 0.01% 223
2015
Q2 		$670K Buy
29,780
+14,958
+101% +$369K 0.01% 246
2015
Q1 		$382K Buy
+14,822
New +$376K ﹤0.01% 617

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ALPS Advisors's OMED Position: Q2 2017 in Review

ALPS Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 31,910 shares — an estimated $294K sold.

ALPS Advisors first reported a position in OMED in Q1 2015 and held it in 9 quarters. The position peaked at $894K in Q4 2015. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • ALPS Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • ALPS Advisors sold 31,910 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $294K.
  • ALPS Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2015 and held it in 9 quarters.
  • ALPS Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $894K in Q4 2015.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on ALPS Advisors's 13F filing for Q2 2017, filed 3 Aug 2017.